Michael A. Kapin
Alcon
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael A. Kapin.
Investigative Ophthalmology & Visual Science | 2011
R. J. Collier; Yamini Patel; E. Martin; Olga Dembinska; Mark R. Hellberg; D. Scott Krueger; Michael A. Kapin; Carmelo Romano
PURPOSE 5-HT(1A) agonists are neuroprotective in CNS injury models. The authors evaluated the efficacy of 5-HT(1A) agonists to protect the retina from severe blue light-induced photo-oxidative damage. METHODS Albino rats were dosed (subcutaneously) with AL-8309A, 8-OH DPAT, or buspirone once or three times before 6-hour exposure to blue light. Electroretinograms (ERGs) were measured to assess retinal function, and retinal damage was evaluated by light microscopy. Topical ocular dosing with 1.75% AL-8309B was also evaluated. Rats were dosed with WAY-100635, a 5-HT(1A) antagonist, to determine whether protection required activation of the 5-HT(1A) receptor. RESULTS ERG response amplitudes were significantly (P < 0.05) depressed more than 66% in vehicle-dosed rats after light exposure. ERGs were significantly higher in rats treated with AL-8309A (0.1-30 mg/kg), 8-OH DPAT (0.1-1 mg/kg), buspirone (5-20 mg/kg) or topical ocular with 1.75% AL-8309B. Retinas from AL-8309A and 8-OH DPAT-treated rats were devoid of histologic lesions. Significant protection was measured in rats dosed once 0, 24, or 48 hours before light exposure. Protection provided by dosing with AL-8309B or 8-OH DPAT was inhibited in rats predosed with WAY-100635. CONCLUSIONS 5-HT(1A) agonists provided potent and complete functional and structural protection. Protection was inhibited by treatment with WAY-100635, confirming the requirement for activating the 5-HT(1A) receptor in initiating this survival pathway. Single-dose experiments with AL-8309A suggest that the mechanism of protection is rapidly activated and protection persists for 48 hours. AL-8309B (1.75%) was effective after topical ocular dosing. AL-8309B is under evaluation in the clinic and may be useful in treating age-related macular degeneration.
Brain Research | 1998
Magali Reyes; Ayesha Reyes; Thoralf Opitz; Michael A. Kapin; Patric K. Stanton
The N-methyl-D-aspartate (NMDA) subtype of glutamate receptor is one pathway through which excessive influx of calcium has been suggested to trigger ischemia-induced delayed neuronal death. NMDA receptors are heterooligomeric complexes comprised of both NR1 and NR2A-D subunits, in various combinations. NR2B-containing NMDA complexes exhibit larger, more prolonged conductances than those lacking this subunit. We tested the ability of the non-competitive, NR2B-selective NMDA antagonist eliprodil to (a) protect synaptic transmission in in vitro hippocampal slices from hypoxia, and (b) reduce ischemic delayed neuronal death in hippocampal organotypic slice cultures. Eliprodil markedly improved the recovery of Schaffer collateral-CA1 excitatory postsynaptic potentials following a 15 min hypoxic insult, with an EC50 of approximately 0.5 microM. In contrast to this functional protection, eliprodil did not reduce delayed death of CA1 pyramidal neurons in organotypic hippocampal slice cultures treated with severe hypoxia plus hypoglycemia, though it did potently protect CA3 pyramidal neurons in the same cultures. These data indicate that NMDA receptors containing NR2B subunits may play a role in long-term recovery of hippocampal synaptic function following ischemia/hypoxia. Furthermore, the selective protection of CA3, but not CA1, pyramidal neurons suggests that NR2B-containing NMDA receptors may preferentially contribute to an excitotoxic component of ischemia-induced delayed neuronal death.
Biochemical and Biophysical Research Communications | 2001
Matthew J. Crawford; Raghu R. Krishnamoorthy; Victoria L. Rudick; Robert J. Collier; Michael A. Kapin; Bharat B. Aggarwal; Muayyad R. Al-Ubaidi; Neeraj Agarwal
Investigative Ophthalmology & Visual Science | 1999
Michael A. Kapin; R Doshi; B Scatton; Louis Desantis; M L Chandler
Archive | 1996
Michael A. Kapin; Louis Desantis
Investigative Ophthalmology & Visual Science | 1999
Iok Hou Pang; Eric M. Wexler; Scott Nawy; Louis Desantis; Michael A. Kapin
Biochemical and Biophysical Research Communications | 2001
Matthew J. Crawford; Raghu R. Krishnamoorthy; Victoria L. Rudick; R. J. Collier; Michael A. Kapin; Bharat B. Aggarwal; Muayyad R. Al-Ubaidi; Neeraj Agarwal
Experimental Eye Research | 2002
Neeraj Agarwal; Elizabeth Martin; Raghu R. Krishnamoorthy; Robert A. Landers; Rong Wen; Scott Krueger; Michael A. Kapin; Robert J. Collier
Archive | 1994
Michael A. Kapin; Louis Desantis; Salomon Langer
Archive | 1995
Iok-Hou Pang; Michael A. Kapin